AP2212A - Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. - Google Patents

Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.

Info

Publication number
AP2212A
AP2212A AP2006003675A AP2006003675A AP2212A AP 2212 A AP2212 A AP 2212A AP 2006003675 A AP2006003675 A AP 2006003675A AP 2006003675 A AP2006003675 A AP 2006003675A AP 2212 A AP2212 A AP 2212A
Authority
AP
ARIPO
Prior art keywords
monophosphonamidates
bisphosphonamidates
phosphonates
treatment
viral diseases
Prior art date
Application number
AP2006003675A
Other languages
English (en)
Other versions
AP2006003675A0 (en
Inventor
Xiaqin Cheng
Gary P Cook
Manoj C Desai
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2006003675A0 publication Critical patent/AP2006003675A0/xx
Application granted granted Critical
Publication of AP2212A publication Critical patent/AP2212A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2006003675A 2003-12-30 2004-12-29 Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. AP2212A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53374503P 2003-12-30 2003-12-30
US59098704P 2004-07-26 2004-07-26
US60659504P 2004-09-01 2004-09-01
PCT/US2004/043969 WO2005066189A1 (en) 2003-12-30 2004-12-29 Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases

Publications (2)

Publication Number Publication Date
AP2006003675A0 AP2006003675A0 (en) 2006-08-31
AP2212A true AP2212A (en) 2011-03-01

Family

ID=34753695

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003675A AP2212A (en) 2003-12-30 2004-12-29 Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.

Country Status (27)

Country Link
US (5) US7553825B2 (pt)
EP (2) EP1716162B1 (pt)
JP (2) JP4949852B2 (pt)
KR (2) KR20120080240A (pt)
CN (2) CN101816664B (pt)
AP (1) AP2212A (pt)
AT (1) ATE478082T1 (pt)
AU (2) AU2004312546B2 (pt)
BR (1) BRPI0418251C1 (pt)
CA (1) CA2550222C (pt)
CY (2) CY1111050T1 (pt)
DE (1) DE602004028763D1 (pt)
DK (2) DK2204374T3 (pt)
EA (1) EA011304B1 (pt)
ES (2) ES2389602T3 (pt)
HR (3) HRP20100626T1 (pt)
IL (1) IL176407A (pt)
IS (1) IS2994B (pt)
NO (2) NO338001B1 (pt)
NZ (1) NZ548771A (pt)
PL (3) PL2204374T3 (pt)
PT (2) PT1716162E (pt)
RS (2) RS51476B (pt)
SG (1) SG149075A1 (pt)
SI (2) SI1716162T1 (pt)
WO (1) WO2005066189A1 (pt)
ZA (1) ZA200606049B (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7214668B2 (en) * 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
AU2003235501A1 (en) * 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
ES2389602T3 (es) * 2003-12-30 2012-10-29 Gilead Sciences, Inc. Fosfonatos de nucleósidos y análogos de los mismos para el tratamiento de infecciones por el VPH
CN1964967B (zh) * 2004-06-08 2014-04-16 症变治疗公司 路易斯酸介导的环状酯的合成
WO2007002808A1 (en) * 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof
WO2007002912A2 (en) * 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
DK2020996T3 (da) * 2006-05-16 2012-02-27 Gilead Sciences Inc Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
ES2437871T3 (es) * 2006-07-07 2014-01-14 Gilead Sciences, Inc. Moduladores del receptor tipo toll 7
WO2008008397A2 (en) 2006-07-14 2008-01-17 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102309984B (zh) * 2011-07-22 2013-05-01 华东师范大学 一种磷酸酰胺类双功能催化剂及其合成方法
WO2013095684A1 (en) 2011-12-22 2013-06-27 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN107056838A (zh) 2013-03-15 2017-08-18 加利福尼亚大学董事会 无环核苷膦酸二酯
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015161781A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 一种核苷类似物及其中间体的制备方法
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016174081A1 (en) * 2015-04-28 2016-11-03 Ku Leuven Research & Development Novel antiviral compounds, a process for their preparation, and their use for treating viral infections
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
CN107849075A (zh) * 2016-01-19 2018-03-27 四川海思科制药有限公司 一种核苷类似物的磷酰胺酯前药及其应用
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
WO2018055071A1 (en) * 2016-09-23 2018-03-29 Katholieke Universiteit Leuven Prodrugs of fluorinated acyclic nucleoside phosphonates
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
MA47094A (fr) 2016-12-22 2021-05-26 Idenix Pharmaceuticals Llc Promédicaments d'ester aliphatique antiviral de ténofovir
CN108276444A (zh) * 2017-01-06 2018-07-13 米文君 一类新的化合物及其用途
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
WO2020067431A1 (ja) * 2018-09-28 2020-04-02 広栄化学工業株式会社 アミデート化合物の製造方法及びアミデート化合物
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
CN118652276B (zh) * 2024-08-19 2024-10-15 成都工业学院 一种用于治疗癌症疾病的化合物的制备工艺
CN118652277A (zh) * 2024-08-19 2024-09-17 成都工业学院 一种用于治疗癌症疾病的化合物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528490C2 (de) * 1975-06-26 1983-04-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung saurer Protease
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
DE69129650T2 (de) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
OA12393A (en) * 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
DE10236294A1 (de) * 2001-08-17 2003-02-27 Alstom Switzerland Ltd Gasversorgungskontrolleinrichtung einer Gasspeicherkraftanlage
CN1168449C (zh) * 2002-12-23 2004-09-29 梁有国 抗人乳头瘤病毒感染的药物
ES2389602T3 (es) * 2003-12-30 2012-10-29 Gilead Sciences, Inc. Fosfonatos de nucleósidos y análogos de los mismos para el tratamiento de infecciones por el VPH

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN ET AL.: "In vivo anti-papilomavirus activity of nucleoside analogues inciudinh cidofovir on CRPV-induced rabbit papillomas" ANTIVIRAL RESEARCH, vol. 48, 2000, pages 131-142 *
KEITH ET AL.: "Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, no. 7, July 2003 (2003-07), pages 2193-2198 *
SNOECK ET AL.: "Antivaccinia Activities of Acyclic Nucleoside Phosphonate Derivatives in Epithelial Cells and Organotypic Cultures" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 11, November 2002 (2002-11), pages 3356-3361 *

Also Published As

Publication number Publication date
CY1113103T1 (el) 2016-04-13
NO20063479L (no) 2006-10-02
IS8516A (is) 2006-06-21
US20060030545A1 (en) 2006-02-09
EA200601263A1 (ru) 2006-12-29
CA2550222C (en) 2013-05-28
AU2011200141B2 (en) 2012-02-16
HRP20100626T1 (hr) 2011-03-31
PT2204374E (pt) 2012-09-17
EP2204374A1 (en) 2010-07-07
SI1716162T1 (sl) 2010-12-31
IL176407A (en) 2012-12-31
JP2011137029A (ja) 2011-07-14
KR101214257B1 (ko) 2012-12-21
SI2204374T1 (sl) 2012-09-28
CN1950383A (zh) 2007-04-18
US20050222090A1 (en) 2005-10-06
SG149075A1 (en) 2009-01-29
BRPI0418251C1 (pt) 2021-05-25
AU2004312546A1 (en) 2005-07-21
PT1716162E (pt) 2010-11-24
JP4949852B2 (ja) 2012-06-13
PL1716162T3 (pl) 2011-02-28
NO20150615L (no) 2005-07-01
EP2204374B1 (en) 2012-06-13
ES2350983T3 (es) 2011-01-28
KR20120080240A (ko) 2012-07-16
US8088754B2 (en) 2012-01-03
NO338040B1 (no) 2016-07-25
CA2550222A1 (en) 2005-07-21
US7553825B2 (en) 2009-06-30
BRPI0418251B1 (pt) 2019-09-24
DK2204374T3 (da) 2012-09-10
CN101816664A (zh) 2010-09-01
ES2389602T3 (es) 2012-10-29
HRP20120699T1 (hr) 2012-09-30
DE602004028763D1 (de) 2010-09-30
AP2006003675A0 (en) 2006-08-31
WO2005066189A1 (en) 2005-07-21
RS52433B (sr) 2013-02-28
US20090149400A1 (en) 2009-06-11
KR20060129360A (ko) 2006-12-15
JP2007517065A (ja) 2007-06-28
IS2994B (is) 2018-03-15
HK1097276A1 (en) 2007-06-22
DK1716162T3 (da) 2011-01-10
NZ548771A (en) 2010-05-28
NO338001B1 (no) 2016-07-18
ZA200606049B (en) 2008-01-08
RS51476B (sr) 2011-04-30
PL2204374T3 (pl) 2012-11-30
ATE478082T1 (de) 2010-09-15
US20060046981A1 (en) 2006-03-02
IL176407A0 (en) 2006-10-05
CN1950383B (zh) 2010-06-09
EP1716162B1 (en) 2010-08-18
US8268802B2 (en) 2012-09-18
HRP20060254A2 (en) 2006-10-31
AU2011200141A1 (en) 2011-02-03
PL212403B1 (pl) 2012-09-28
CY1111050T1 (el) 2015-06-11
CN101816664B (zh) 2012-04-18
EP1716162A1 (en) 2006-11-02
US20090291922A1 (en) 2009-11-26
EA011304B1 (ru) 2009-02-27
HK1146061A1 (en) 2011-05-13
BRPI0418251B8 (pt) 2019-10-08
BRPI0418251A (pt) 2007-04-17
AU2004312546B2 (en) 2010-10-14
PL380828A1 (pl) 2007-03-19

Similar Documents

Publication Publication Date Title
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
EG25148A (en) Process for the manufacture of 1,2-dichloroethane.
EG25281A (en) Process for the manufacture of 1,2-dichloroethane.
EP1594512A4 (en) COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AP2005003232A0 (en) Combination therapy for hyperproliferative diseases.
EP1545558A4 (en) 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
AP2006003514A0 (en) Piperazine derivatives for the treatment of HIV infections.
HRP20050328A2 (en) Process for the preparation of (s,s)-cis-2-benzhyd
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
SI1663244T1 (sl) Pteridinski derivati za zdravljenje bolezni, povezanih s TNF-alfa
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.
AU2003284212A8 (en) Process for the preparation of (s,s)-cis-2-phenyl-3-aminopiperidine
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
ITUD20030080A1 (it) Procedimento per effettuare transazioni commerciali.
GB0315877D0 (en) Compounds for the treatment of disease